Vaginal Atrophy

Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. Because the condition is attributable to estrogen deficiency, it may occur in premenopausal women who take antiestrogenic medications or who have medical or surgical conditions that result in decreased levels of estrogen.

The thinned endometrium and increased vaginal pH level induced by estrogen deficiency predispose the vagina and urinary tract to infection and mechanical weakness. The earliest symptoms are decreased vaginal lubrication, followed by other vaginal and urinary symptoms that may be exacerbated by superimposed infection. Once other causes of symptoms have been eliminated, treatment usually depends on estrogen replacement.

Estrogen replacement therapy may be provided systemically or locally, but the dosage and delivery method must be individualized. Vaginal moisturisers and lubricants, and participation in coitus may also be beneficial in the treatment of women with atrophic vaginitis

Because of declining estrogen levels, women who are in mid-life or beyond often present with symptoms of atrophic vaginitis. An estimated 10 to 40 percent of postmenopausal women have symptoms of atrophic vaginitis, also referred to as urogenital atrophy.¹

Despite the prevalence of symptoms, only 20 to 25 percent of symptomatic women seek medical attention.^2,3 Therefore, physicians have an opportunity to improve the urogenital health and quality of life of a large patient population throughidentification of and intervention in this often overlooked and underdiagnosed condition.